Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q3 2015 (← Previous) (Next →)

Filing Date: Oct 28, 2015

Total Value ($000): $174,363,358 (100.0% shares, 0.0% debt)

Holdings (7)

GKOS Glaukos Corporation 43.6%

Value ($000) $76,010,229 Shares 3,142,217 Est. Cost $30.09 Unrealized 0.0%

— Clovis Oncology, Inc. 21.5%

Value ($000) $37,465,975 Shares 407,416 Est. Cost $56000.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 17.9%

Value ($000) $31,148,299 Shares 2,215,384 Est. Cost $20.09 Unrealized 0.0%

— Five Prime Therapeutics, Inc. 9.6%

Value ($000) $16,808,219 Shares 1,092,152 Est. Cost $27000.00 Unrealized —

— Achaogen, Inc. 4.2%

Value ($000) $7,379,435 Shares 1,281,152 Est. Cost $13050.00 Unrealized —

— Biotie Therapies Corp. 2.0%

Value ($000) $3,516,916 Shares 268,672 Est. Cost $19970.00 Unrealized —

— CymaBay Therapeutics, Inc. 1.2%

Value ($000) $2,034,285 Shares 1,048,601 Est. Cost $9830.00 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
GKOS	Glaukos Corporation	3,142,217	$76,010,229	43.6%	$30.09	0.0%	Common Stock	377322102
—	Clovis Oncology, Inc.	407,416	$37,465,975	21.5%	$56000.00	—	Common Stock	189464100
OCUL	Ocular Therapeutix, Inc.	2,215,384	$31,148,299	17.9%	$20.09	0.0%	Common Stock	67576A100
—	Five Prime Therapeutics, Inc.	1,092,152	$16,808,219	9.6%	$27000.00	—	Common Stock	33830X104
—	Achaogen, Inc.	1,281,152	$7,379,435	4.2%	$13050.00	—	Common Stock	004449104
—	Biotie Therapies Corp.	268,672	$3,516,916	2.0%	$19970.00	—	ADS	09074D103
—	CymaBay Therapeutics, Inc.	1,048,601	$2,034,285	1.2%	$9830.00	—	Common Stock	23257D103